Dystonia Drugs Market Is Expected to Reach $1378.67 Million by 2031: Says AMR

Increase in R&D activities in pharmaceutical field, increase in incidences of dystonia and increase in prevalence of neurological disorders drives the growth of the global dystonia drugs market. By drug type, the GABAergic agents segment garnered the major share in 2021. By region, Asia-Pacific would grow with the fastest CAGR by 2031.


Portland, OR, March 08, 2023 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global dystonia drugs market was valued at $806.67 million in 2021, and is projected to reach $1,378.67 million by 2031, registering a CAGR of 5.5% from 2022 to 2031. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

Download Report Sample for Free- https://www.alliedmarketresearch.com/request-sample/14307

Report coverage & details:

Forecast Period2022–2031
Base Year2021
Market Size in 2021$806.67 Million
Market Size in 2031$1378.67 Million
CAGR5.5%
No. of Pages in Report250
Segments CoveredDrug Type, Route of Administration, Distribution Channel and Region.
Drivers Increase in R&D activities in pharmaceutical field
Increase in incidences of dystonia 
Increase in prevalence of neurological disorders 
RestraintsLack of awareness about dystonia in underdeveloped nations
OpportunitiesGrowth opportunity in emerging markets

Impact of Covid-19 on Dystonia Drugs Market-

  • The COVID-19 outbreak had a negative impact on growth of the global dystonia drugs market. The pandemic has forced a number of industries to halt their activities temporarily, including several subdomains of health care.
  • There was a negative impact on the market due to decreased sales of dystonia drugs and medications due to decreased patient visit to the hospitals. Also, non-COVID-19 hospitalizations started to decline which suggested that people were delaying care due to the pandemic, due to hospital capacity constraints and threat due to corona virus infection.

Procure Complete Report (260 Pages PDF with Insights, Charts, Tables, and Figures)
https://www.alliedmarketresearch.com/checkout-final/dystonia-drugs-market

The global dystonia drugs market is analyzed across drug type, route of administration, distribution channel, and region. The study utilizes tabular and graphical representation to offer a thorough study of the segments and their sub-segments. The segmentation can assist investors and market participants to build strategies based on the top revenue-generating and fastest-growing segments identified by the study.

By drug type, the GABAergic agents segment held the largest share in 2021, garnering more than one third of the global dystonia drugs market revenue, and is expected to maintain its dominance by 2031 with a highest CAGR of 6.4% during the forecast period.

By route of administration, the oral segment contributed to nearly three-fourth of the global dystonia drugs market share in 2021, and is projected to dominate the market till 2031. On the other hand, injectable segment is projected to growth at a fastest CAGR of 6.6% during the forecast period.

By distribution channel, the drug stores and retail pharmacies segment accounted for the highest share in 2021, generating around more than half of the global dystonia drugs market revenue. On the other hand, online providers segment would grow at a fastest CAGR of 6.5% during the forecast period.

For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/14307

By region, North America held the major share in 2021, garnering more than two-fifth of the global dystonia drugs market revenue. Asia-Pacific, simultaneously, would exhibit the fastest CAGR of 7.2% from 2022 to 2031.

The key market players analyzed in the global dystonia drugs market report include AbbVie Inc., Amneal Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd, Hameln Pharma GmbH, Ipsen Pharma, Merz Pharmaceuticals, LLC, Novartis AG, Pfizer Inc., Teva Pharmaceuticals and Wellona Pharma. These market players have embraced several strategies including product approval, collaboration, acquisition, clinical trials, agreement and product launch, and others to highlight their expertise in the market. The report is useful for analyzing the developments and business performance of the major companies. 

Similar Research Reports for Information, Communication and Technology:

Medical Display Market - Opportunity Analysis and Industry Forecast, 2021–2030

Mobile Gamma Cameras Market- Opportunity Analysis and Industry Forecast, 2021–2030

Healthcare Chatbots Market - Global Opportunity Analysis and Industry Forecast, 2021–2030

Hybrid Operating Room Market- Global Opportunity Analysis and Industry Forecast, 2021–2030

Workplace Wellness Market - Global Opportunity Analysis and Industry Forecast, 2021–2030

                                                                                 
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model):

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com 
Web: https://www.alliedmarketresearch.com